Progress and prospects: Graft-versus-host disease

Gene Therapy

Volumn 17, Issue 11, 2010, Pages 1309-1317

  Mastaglio, S ^a,b,c,d   Stanghellini, M T L ^a,b   Bordignon, C ^c,d   Bondanza, A ^a,b   Ciceri, F ^a,b,c   Bonini, C ^a,b,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Gene Therapy Program   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d MOLMED S P A   (Italy)

Author keywords

allogeneic stem cell transplantation; cell therapy; GvHD; T cells

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL; GENE TECHNOLOGY; GENE TRANSFER; GRAFT VERSUS HOST REACTION; HUMAN; INFECTIOUS COMPLICATION; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; T CELL DEPLETION;

ANIMALS; GENE THERAPY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 78149465527     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.83     Document Type: Review

References (80)

1. Baker KS, Fraser CJ. Quality of life and recovery after graft-versus-host disease. Best Pract Res Clin Haematol. 2008;21:333-341.
2. Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109: 4119-4126.
3. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009; 43: 275-291.
4. Aversa F, Reisner Y, Martelli MF. The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis 2008; 40: 8-12.
5. Huang XJ. Current status of haploidentical stem cell transplan¬tation for leukemia. J Hematol Oncol 2008; 1: 27.
6. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 2: 1550-1561.
7. Dickinson AM, Holler E. Polymorphisms of cytokine and innate immunity genes and GVHD. Best Pract Res Clin Haematol 2008; 21: 149-164.
8. Biedermann BC. Vascular endothelium and graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 129-138.
9. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111: 2470-2475.
10. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340-352.
11. Riddell SR, Appelbaum FR. Graft-versus-host disease: a surge of developments. PLoS Med 2007; 4: 198.
12. Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009; 23: 78-84.
13. Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol 2007; 137: 87-98.
14. Soiffer R. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant 2008; 42 (Suppl 1): S66-S69.
15. Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematol Am Soc Hematol Educ Program 2008; 2008: 134-141.
16. Barrett AJ, Le Blanc K. Prophylaxis of acute GVHD: manipulate the graft or the environment? Best Pract Res Clin Haematol 2008; 21: 165-176.
17. Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ et al. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 920-926.
18. Schleuning M, Judith D, Jedlickova Z, Stübig T, Heshmat M, Baurmann H et al. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant 2008; 43: 717-723.
19. Besien KV, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 610-617.
20. Kroger N, Zabelina T, Binder T, Ayuk F, Bacher U, Amtsfeld G et al. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymo-cyte globulin-containing conditioning regimen. Biol Blood Marrow Transplant 2009; 15: 454-462.
21. Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009; 145: 816-824.
22. Christopeit M, Schütte V, Theurich S, Weber T, Grothe W, Behre G. Rituximab reduces the incidence of acute graft-versus-host disease. Blood 2009; 113: 3130-3131.
23. Berger C, Turtle CJ, Jensen MC, Riddell SR. Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 2009; 21: 224-232.
24. Feuchtinger T, Richard C, Joachim S, Scheible MH, Schumm M, Hamprecht K et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 2008; 31: 199-206.
25. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 2008; 82: 546-554.
26. Karlsson H, Brewin J, Kinnon C, Veys P, Amrolia PJ. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens. J Immunother 2007; 30: 544-556.
27. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplan¬tation. Blood 2009; 114: 4283-4292.
28. Fujita Y, Leen AM, Sun J, Nakazawa Y, Yvon E, Heslop H et al. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother 2008; 31: 665-674.
29. Spierings E. Minor histocompatibility antigens: targets for tumour therapy and transplant tolerance. Int J Immunogenet 2008; 35: 363-366.
30. Wehler TC, Nonn M, Brandt B, Britten CM, Gröne M, Todorova M et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from anti-leukemic and antitumor donor T-cell lines. Blood 2007; 109: 365-373.
31. Hartwig UF, Nonn M, Khan S, Link I, Huber C, Herr W. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. Biol Blood Marrow Transplant 2008; 14: 99-109.
32. Mielke S, Nunes R, Rezvani K, Fellowes VS, Venne A, Solomon SR et al. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 2008; 111: 4392-4402.
33. Perruccio K, Topini F, Tosti A, Carotti A, Aloisi T, Aversa F et al. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis 2008; 40: 76-83.
34. Matte-Martone C, Liu J, Jain D, McNiff J, Shlomchik WD. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. Blood 2008; 111: 3884-3892.
35. Dutt S, Tseng D, Ermann J, George TI, Liu YP, Davis CR et al. Naive and memory Tcells induce different types of graft-versus-host disease. J Immunol 2007; 179: 6547-6554.
36. Zheng H, Matte-Martone C, Li H, Anderson BE, Venketesan S, Sheng Tan H et al Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 2008; 111: 2476-2484.
37. Chen BJ, Deoliveira D, Cui X, Le NT, Son J, Whitesides JF et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 2007; 109: 3115-3123.
38. Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F et al. Haploidentical stem cell transplantation following a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: post-transplant CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009; 113: 4771-4779.
39. Toubai T, Sun Y, Reddy P. GVHD pathophysiology: is acute different from chronic? Best Pract Res Clin Haematol 2008; 21: 101-117.
40. von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009; 43: 245-251.
41. Baker M. Stem-cell drug fails crucial trials. Nature 2009; e-pub ahead of print 9 September 2009.
42. Nguyen VH, Shashidhar S, Chang DS, Ho L, Kambham N, Bachmann M et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 2008; 111: 945-953.
43. Edinger M, Powrie F, Chakraverty R. Regulatory mechanisms in graft-versus-host responses. Biol Blood Marrow Transplant 2008; 15: 2-6.
44. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res 2007; 150: 197-214.
45. Allan SE, Broady R, Gregori S, Himmel ME, Locke N, Roncarolo MG et al. CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev 2008; 223: 391-421.
46. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-rando¬mised phase I-II study. Lancet Oncol 2009; 10: 489-500.
47. Bonini C, Bondanza A, Perna SK, Kaneko S, Traversari C, Ciceri F et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 2007; 15: 1248-1252.
48. Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M et al. Antitumor effects of HSV-TK-engineered donor lympho¬cytes after allogeneic stem-cell transplantation. Blood 2007; 109: 4698-4707.
49. Deschamps M, Robinet E, Certoux JM, Mercier P, Sauce D, De Vos J et al. Transcriptome of retrovirally transduced CD8+ lymphocytes: influence of cell activation, transgene integration, and selection process. Mol Immunol 2008; 45: 1112-1125.
50. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et al. A survey of fully-haploidentical hematopoietic stem cells transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients transplanted in remis¬sion. Blood 2008; 112: 3574-3581.
51. Bennour E, Ferrand C, Rémy-Martin JP, Certoux JM, Gorke S, Qasim W et al. Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance. Hum Gene Ther 2008; 19: 699-709.
52. Kaneko S, Mastaglio S, Bondanza A, Ponzoni M, Sanvito F, Aldrighetti L et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009; 113: 1006-1015.
53. Traversari C, Marktel S, Magnani Z, Mangia P, Russo V, Ciceri F et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007; 109: 4708-4715.
54. Mercier-Letondal P, Deschamps M, Sauce D, Certoux JM, Milpied N, Lioure B et al. Early immune response against retrovirally-transduced herpes simplex virus-thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response? Hum Gene Ther 2008; 19: 937-950.
55. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 913-924.
56. Nakazawa Y, Huye LE, Dotti G, Foster AE, Vera JF, Manuri PR et al. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother 2009; 32: 826-836.
57. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-546.
58. Burns WR, Zheng Z, Rosenberg SA, Morgan RA. Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 2009; 114: 2888-2899.
59. Van Loenen MM, Hagedoorn RS, Kester MG, Hoogeboom M, Willemze R, Falkenburg JH et al. Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells. Cancer Res 2009; 69: 2034-2041.
60. Teague RM, Greenberg PD, Fowler C, Huang MZ, Tan X, Morimoto J et al. Peripheral CD8+ Tcell tolerance to self-proteins is regulated proximally at the T cell receptor. Immunity 2008; 28: 662-674.
61. Heemskerk MH, Hagedoorn RS, van der Hoorn MA, van der Veken LT, Hoogeboom M, Kester MG et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007; 109: 235-243.
62. Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109: 2331-2338.
63. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007; 67: 3898-3903.
64. Hart DP, Xue SA, Thomas S, Cesco-Gaspere M, Tranter A, Willcox B et al. Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. Gene Therapy 2008; 15: 625-631.
65. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112: 2261-2271.
66. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 2009; 32: 169-180.
67. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008; 68: 2961-2971.
68. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007; 25: 243-265.
69. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21: 215-223.
70. Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: 'Are we nearly there yet?'. Hum Gene Ther 2009; 20: 1229-1239.
71. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009; 113: 6392-6402.
72. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371-4383.
73. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233-5239.
74. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-2703.
75. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118: 294-305.
76. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007; 110: 2793-2802.
77. Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM et al. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 2009; 17: 880-888.
78. Qasim W, Mackey T, Sinclair J, Chatziandreou I, Kinnon C, Thrasher AJ et al. Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction. Mol Ther 2007; 15: 355-360.
79. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25: 1298-1306.
80. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008; 26: 808-816.